The review, led by George W. Koutsouras and Michael C. Dewan of Vanderbilt University Medical Center together with colleagues at the Barrow Neurological Institute, Princess Margaret Cancer Centre, and The Hospital for Sick Children, synthesizes the contemporary literature on molecular classification, imaging, and treatment outcomes for posterior fossa ependymoma. Its central message is that the World Health Organization’s shift from a purely histologic framework to molecularly integrated entities has finally caught up with the biology. Posterior fossa ependymoma group A (PFA) and group B (PFB) are not grades of the same tumor but separate diseases with different epigenetic engines, different age distributions, different imaging signatures, and sharply different prognoses.

The biological fault line runs through the epigenome. PFA tumors, which predominate in younger children with a median age of about five years, show a global loss of the repressive histone mark H3K27me3. This loss stems from inhibition of the polycomb repressive complex 2, the molecular machine that normally silences genes by trimming histone proteins, and the inhibition is commonly driven by overexpression of a protein called EZHIP, which mimics the notorious K27M oncohistone mechanism. The result is widespread derepression of developmental gene programs that fuel tumor growth. PFB tumors, by contrast, retain their H3K27me3 mark, preserve PRC2 function, and instead carry numerous arm-level chromosomal gains and losses, a pattern of somatic aneuploidy that paradoxically accompanies a more indolent clinical course. Within PFA itself, the review highlights an even more ominous stratum: tumors with chromosome 1q gain and/or 6q loss form a very high-risk group marked by increased recurrence, metastatic spread, and poor survival even after gross total resection and upfront radiotherapy.

Clinically, the two subgroups announce themselves differently. Children with posterior fossa ependymomas typically present with headache, nausea, vomiting, lethargy, and gait disturbance, the consequences of obstructive hydrocephalus as the tumor blocks cerebrospinal fluid flow from the fourth ventricle, often accompanied by truncal ataxia and sometimes lower cranial nerve deficits. Symptom onset can be insidious, and a long history of vomiting without headache may delay diagnosis. But PFA tumors tend to arise in younger children, carry a larger tumor burden, and produce more pronounced hydrocephalus, while PFB tumors appear in adolescents and adults and behave less aggressively. Even magnetic resonance imaging reflects the molecular divide: PFA tumors more often show larger volume, hydrocephalus, lateral extension through the skull base, and lower apparent diffusion coefficient values, whereas PFB tumors are typically more homogeneous, circumscribed, and cystic. The authors recommend craniospinal MRI at diagnosis, during surveillance, and at recurrence, noting that thin-cut T2-weighted spinal imaging is essential because metastatic deposits may not enhance.

When it comes to treatment, the review is unambiguous about the hierarchy of interventions. Surgery remains the single most important component of care, and the extent of resection is the key modifiable determinant of disease control. The evidence is striking. In the Children’s Oncology Group ACNS0121 study, gross total resection followed by immediate conformal radiotherapy yielded a five-year event-free survival of 68.5 percent and overall survival of 86.2 percent, compared with 37.2 percent and 70.2 percent for subtotal resection followed by adjuvant therapy. A posterior fossa-specific study by Silva da Costa and colleagues found median overall survival of 136 months after gross total resection versus 38 months after subtotal resection, with progression-free survival of 40 versus 7 months. The authors caution, however, that most surgical series are retrospective and that extent of resection partly reflects tumor anatomy, biology, and institutional experience rather than a pure treatment effect. Notably, adverse PFA biology, particularly 1q gain and 6q loss, may attenuate the survival benefit of complete resection, meaning that even a perfect operation cannot fully overcome hostile molecular terrain.

The surgical challenge itself is formidable. These tumors arise from the fourth ventricle and frequently extend through the foramina of Luschka and Magendie, wrapping around cranial nerve nuclei, the brainstem, and the vertebrobasilar circulation. In a recent molecularly defined pediatric cohort, cranial neuropathies occurred in 60 percent of patients after primary resection, though 56 percent of those resolved within a year. The review describes operative adjuncts in detail: prone positioning with individualized head fixation, since pin fixation in children under two risks calvarial injury; intraoperative neuromonitoring with spontaneous EMG recordings of cranial nerves; neuronavigation, ultrasound, and intraoperative MRI; and external ventricular drain placement, given that hydrocephalus affects up to 80 percent of children with a posterior fossa mass. When residual disease remains, early second-look surgery at an experienced center is favored, and complex ventral extension may occasionally require staged operations, always balanced against the morbidity of delaying adjuvant therapy.

Radiation therapy forms the second pillar of treatment. Postoperative focal radiotherapy is recommended for most children with localized disease after maximal safe resection, typically at a dose of 59.4 Gy, reduced to 54 Gy in selected very young patients after complete resection. Contemporary conformal techniques, including proton therapy, have progressively reduced the exposure of healthy tissue: Children’s Oncology Group protocols shrank clinical target volume margins from 10 millimeters in ACNS0121 to 5 millimeters in ACNS0831, limiting dose to normal brain and cerebellum. Proton therapy offers dosimetric advantages with disease control comparable to photon treatment, though the authors note there is no high-quality data directly comparing toxicity between modalities, and prescription doses for protons still vary from 54 to 59.4 GyE because of concerns about brainstem toxicity. Craniospinal irradiation is generally reserved for metastatic disease or recurrence, and failure after treatment remains predominantly local, underscoring that radiation efficacy depends on dose, technique, target definition, and the extent of resection achieved.

Chemotherapy, by contrast, has little to no definitive role. The randomized ACNS0831 trial found that adding four cycles of vincristine, cyclophosphamide, etoposide, and cisplatin to radiotherapy did not improve outcomes across the overall cohort, and the ACNS1021 trial showed that the targeted agent sunitinib produced no sustained objective responses. Historical baby-brain protocols that deferred radiation in children under three achieved five-year progression-free survival of at most 42 percent, while early conformal radiotherapy in comparable populations pushed seven-year progression-free survival toward 77 percent, a comparison that drove the field away from radiation-deferral strategies in children older than 12 months. One emerging exception is molecularly directed therapy: preclinical work by Griesinger and colleagues identified 1q-gain PFA as the highest-risk subgroup and demonstrated sensitivity to 5-fluorouracil and all-trans retinoic acid, a finding the review flags as a promising avenue for future investigation.

Recurrence remains the disease’s cruelest feature, occurring in up to 48 percent of cases with mortality approaching 50 percent despite multimodal therapy, and mean survival after first recurrence of roughly 31 months. More than 80 percent of recurrent infratentorial ependymomas are PFA tumors, with post-recurrence survival of 24.7 months compared with 48 months for PFB. Tumor biology evolves at relapse: 1q gain and 6q loss are enriched at recurrence, and 1q gain shortens the latency to relapse from 25.3 to 14.7 months. Recurrence can appear up to a decade after treatment, sometimes with spinal or supratentorial dissemination, which is why the authors emphasize prolonged surveillance with serial brain and spine MRI tailored to molecular risk. At relapse, management hinges on resectability: repeat surgery, even for multiply recurrent disease, is associated with improved survival, and selective re-irradiation, including craniospinal re-irradiation for posterior fossa primaries, may extend control. The review’s overall vision is a risk-adapted framework in which methylation profiling, copy number analysis, imaging biomarkers, and modern radiotherapy converge to individualize care, with treatment de-escalation for favorable PFB tumors tested only in prospective trials and molecularly directed therapies offering the clearest hope for the children whose tumors, until now, have defied every conventional weapon thrown at them.

Subject of Research: Molecular classification and management of pediatric posterior fossa ependymoma, focusing on the distinct PFA and PFB subgroups

Article Title: Posterior fossa ependymoma: a comprehensive review of molecular classification, management guidelines, and clinical outcomes (Part I of ependymomas across compartments)

Article References: Koutsouras, G. W., Rivera, F., Price, A. M., Tsang, D. S., Esbenshade, A., Ramaswamy, V., Dirks, P. B., & Dewan, M. C. (2026). Posterior fossa ependymoma: a comprehensive review of molecular classification, management guidelines, and clinical outcomes (Part I of ependymomas across compartments). Journal of Neuro-Oncology, 179(3), Article 96. https://doi.org/10.1007/s11060-026-05808-9

Image Credits: AI Generated

DOI: 10.1007/s11060-026-05808-9

Keywords: posterior fossa ependymoma, PFA, PFB, H3K27me3, EZHIP, pediatric brain tumor, gross total resection, conformal radiotherapy, proton therapy, chromosome 1q gain, 6q loss, molecular classification

Lower-grade gliomas occupy an uneasy middle ground in neuro-oncology. They can smolder quietly for years, sometimes over a decade, allowing patients to work, drive and live largely normal lives under watchful surveillance. Yet nearly half of the patients in the new cohort — 77 of 155 — eventually underwent malignant transformation, the biological inflection point in which a slow-growing tumor acquires the aggressive behavior of a high-grade glioma and drives prognosis, adjuvant-therapy decisions and eligibility for clinical trials. Predicting which tumors will take that turn, and when, has remained one of the field’s most stubborn uncertainties, largely because transformation can only be pinned down retrospectively, at the moment a confirmatory MRI or a repeat biopsy reveals it.

The Austrian-led team attacked this problem from several angles simultaneously. Every patient had histologically confirmed adult-type diffuse glioma, diagnostic-quality multiparametric MRI including pre- and post-contrast T1, T2 and FLAIR sequences, and at least one follow-up scan. The time origin for each patient was the first MRI showing the glioma — a deliberately chosen anchor, since 18 patients in the cohort were managed with a wait-and-see strategy for more than a year, with one waiting 17.3 years before histological confirmation, contributing their untreated natural history to the analysis. Because malignant transformation is only ascertainable between examinations, the researchers bracketed each event within an interval bounded by the last documentation of low-grade status and the first examination showing transformation, rather than falsely assigning the event to a single scan date.

That methodological choice mattered enormously. When the team compared conventional dating — which treats the confirmatory scan as the moment of transformation — with proper interval-censored analysis, the conventional approach overstated the hazard of transformation roughly four-fold. The finding exposes a systematic bias running through much of the existing literature, where standard right-censored Cox models equate radiological detection with biological occurrence, an error whose magnitude grows with the length of the surveillance interval. To ensure their conclusions were not artifacts of any single statistical specification, the investigators cross-checked the primary Bayesian interval-censored Weibull model, fitted with a regularized horseshoe prior across 102 candidate predictors, against three frequentist alternatives: a Fine-Gray subdistribution-hazards model accounting for the competing risk of death without transformation, a Cox counting-process model handling surgery as a time-varying covariate with 20-fold multiple imputation, and a native interval-censored Fine-Gray model estimated by sieve maximum likelihood. All four agreed on the direction and significance of the central result.

And that central result was striking. Contrast enhancement visible on the diagnostic scan — even the subtle, sub-threshold kind that does not itself meet radiological criteria for malignancy — was by far the strongest predictor of subsequent malignant transformation, dwarfing both tumor volume and a co-analyzed panel of 99 quantitative radiomic features. In the full cohort, the Bayesian hazard ratio for enhancement reached 22.1, with a 95 percent credible interval of 10.5 to 53.2. Within IDH-mutant disease the association approached separation: all 22 enhancing tumors eventually transformed, compared with only 30 percent of non-enhancing ones, a pattern so extreme that the statisticians had to deploy Firth penalized-likelihood and exact conditional methods to obtain interpretable lower bounds. The same held true across every molecular entity represented — IDH-mutant astrocytomas, 1p/19q-codeleted oligodendrogliomas and IDH-wildtype tumors — with every single enhancing tumor in each subgroup ultimately transforming.

Critically, the team recognized that much of this dramatic unadjusted effect reflects tumors that were already transforming at or near diagnosis, so they performed a prespecified series of landmark analyses that condition on surviving transformation-free for three, six or twelve months and restart the clock there. Even under this stricter framing, a five- to seven-fold elevation in hazard persisted at every landmark: 7.41 at three months, 5.65 at six months and 6.33 at twelve months. The authors note that an unmeasured confounder would need an implausibly strong association with both enhancement and transformation — a risk ratio of at least 5.8 with each — to explain away the six-month estimate. Blinded re-reading of baseline scans by two independent reviewers achieved perfect agreement on enhancement status, and sensitivity analyses excluding patients who would meet the 2021 WHO grade 4 criteria left the effect essentially unchanged.

Perhaps the most surprising discovery concerned what happened after surgery. Because the exposure and the endpoint are both read from post-contrast imaging, one might suspect the enhancement signal simply marks a focus of high-grade disease that a resection removes. The data say otherwise. In a model of time from first surgery restricted to the 128 patients who had not transformed beforehand, baseline enhancement predicted post-surgical malignant transformation with a hazard ratio of 4.28 — and the effect not only persisted within gross-totally resected tumors, where any enhancing tissue present at baseline should have been removed, but strengthened under multivariable adjustment, rising to 7.58 when grade, IDH status and extent of resection were accounted for. Seven of eight enhancing tumors resected gross-totally still transformed, versus only 15 of 60 non-enhancing ones. A signal that outlives the very tissue generating it, the authors argue, points to a property of the tumor as a whole — an intrinsic biology — rather than a discrete focus awaiting excision.

Surgery itself emerged as the only modifiable determinant in the study. Gross-total resection was associated with a roughly two-thirds reduction in the post-surgical hazard of transformation compared with biopsy (hazard ratio 0.32), a benefit also seen within IDH-mutant disease, while subtotal resection showed no significant advantage over biopsy. The finding reinforces the current standard of early onco-functional resection in diffuse glioma, though the authors are careful to note that the timing of surgery in their retrospective cohort was confounded by indication — surgeons often operated precisely because early signs of transformation appeared — and cannot be interpreted causally. What they do propose is that baseline enhancement, currently discarded once histology becomes available, should be carried forward into postoperative risk estimation, where it independently refines prognostication alongside grade, molecular status and resection extent.

The study also delivered a sobering verdict on radiomics. Despite extracting 428 features from co-registered image volumes, reduced to 99 candidates by correlation filtering, not a single quantitative feature survived Bayesian horseshoe shrinkage or native interval-censored analysis. One texture feature retained significance only under the biased midpoint-imputation framework, collapsing to null under proper censoring — a conditional null the authors frame honestly, acknowledging that 77 events cannot credibly support 99 candidate biomarkers, and calling for radiomics discovery to be re-scoped toward predefined panels or much larger cohorts. With a bootstrap-corrected concordance of 0.83 but imperfect absolute-risk calibration, the team explicitly declines to offer their model for individual prediction. Instead, they position the work as a recalibration of the field’s foundations: contrast enhancement on the diagnostic scan deserves a central place in pre- and postoperative risk stratification, gross-total resection materially changes the transformation hazard, and any future estimate of when a lower-grade glioma will turn malignant should respect the interval-censored reality of how that event is actually observed.

Subject of Research: Predictors and timing of malignant transformation in lower-grade glioma using interval-censored survival analysis

Article Title: Malignant transformation of lower-grade glioma: contrast enhancement, extent of resection, and the natural history under interval-censored analysis

Article References: Malignant transformation of lower-grade glioma: contrast enhancement, extent of resection, and the natural history under interval-censored analysis. (n.d.). https://doi.org/10.1007/s11060-026-05803-0

Image Credits: AI Generated

DOI: 10.1007/s11060-026-05803-0

Keywords: lower-grade glioma, malignant transformation, contrast enhancement, MRI, extent of resection, gross-total resection, interval censoring, Bayesian analysis, radiomics, IDH status, WHO classification, brain tumor

The research, published in the Journal of Neuro-Oncology, comes from a team led by Panagiotis Fistouris and senior author Uta Schick at the Department of Neurosurgery of Clemenshospital Muenster, an academic hospital of Muenster University in Germany, with collaborators from the University of Freiburg and Aristotle University of Thessaloniki. In a retrospective analysis of 34 patients treated for spheno-orbital meningiomas, the authors describe a standardized institutional protocol that merges two traditionally separate phases of care: microsurgical tumor resection and immediate cranio-orbital reconstruction using implants planned preoperatively with computer-aided design and computer-aided manufacturing, commonly abbreviated CAD/CAM.

The clinical problem these tumors pose is distinctive. Unlike many brain tumors whose danger lies in what they compress within the cranium, spheno-orbital meningiomas announce themselves largely through the eye. In this series, exophthalmos, the abnormal protrusion of the eyeball, was the predominant presenting symptom. The tumor’s bony overgrowth narrows the orbit from behind, shoving the eye forward and outward, and can also crowd the optic canal, the narrow bony tunnel through which the optic nerve travels from the eye to the brain. Left unchecked, the combination of proptosis, restricted eye movement and optic nerve compromise can produce progressive visual loss and profound cosmetic deformity, which is why surgical treatment typically requires not only tumor removal but also drilling away hyperostotic bone, decompressing the orbit and reconstructing the skull base.

Historically, that reconstruction has been the weak link. Surgeons have either shaped reconstructive materials free hand during the operation or deferred the cranio-orbital rebuild to a delayed second-stage procedure weeks or months later. Both strategies carry drawbacks. Free-hand reconstruction depends heavily on the operator’s judgment in the middle of a long operation, and results can fall short of ideal skull and facial symmetry. Staged procedures, meanwhile, expose patients to a second anesthesia, a second hospitalization and a longer overall recovery, while scar tissue and postoperative swelling from the first operation can make the delayed reconstruction harder to plan and execute accurately. The Muenster group’s protocol was designed to eliminate both problems by planning the entire operation, resection and reconstruction alike, on the computer before the patient ever enters the operating room.

The workflow hinges on preoperative imaging and digital modeling. Using the patient’s computed tomography data, the surgical team maps the extent of tumor infiltration and hyperostosis across the sphenoid wing and orbital walls, simulates the bony defects that will remain after resection and drilling, and then designs a patient-specific implant that will restore the contours of the orbit and cranial vault. The CAD/CAM process produces an implant whose geometry matches the anticipated defect, so that once the tumor is out and the abnormal bone is drilled away, the prosthesis can be seated immediately, restoring orbital volume and facial symmetry in the same anesthetic session. This approach builds on a growing body of work in which three-dimensional printing and computer-assisted design have been applied to customized bone reconstruction in spheno-orbital meningiomas and to single-step cranio-orbital reconstruction with patient-specific polyetheretherketone implants after resection of benign spheno-orbital tumors.

The results of applying this standardized protocol to 34 consecutive patients are striking in several respects. Gross-total resection, the complete removal of visible tumor, was achieved in 73.5 percent of cases, a respectable figure for lesions that infiltrate bone and wrap around critical structures at the skull base. More importantly for patients’ daily lives, the surgery delivered on its functional promises: exophthalmos was reduced in 85 percent of patients, and visual acuity improved in approximately 70 percent. For a disease whose most feared consequences are a bulging, disfigured eye and creeping blindness, those numbers represent a meaningful shift in what patients can expect from surgery.

The outcome data also lay bare the risks that remain inherent to operating in this crowded anatomical corridor. Postoperative amaurosis, blindness of the affected eye, occurred in 8.8 percent of patients, a sobering reminder of how vulnerable the optic nerve is during dissection around the optic canal and orbital apex. Transient diplopia, double vision, was far more common, affecting 55.9 percent of patients, presumably reflecting disturbance of the extraocular muscles and orbital mechanics during decompression and reconstruction. The double vision was temporary, but its frequency underscores that even a meticulously planned single-stage operation cannot fully insulate patients from the functional toll of major orbital surgery. Balancing aggressive bone and tumor removal against preservation of the delicate neurovascular structures threading through the orbit remains the central technical tension of this disease.

On the reconstruction side, however, the report is notably reassuring. The CAD/CAM implants demonstrated appropriate intraoperative fit, meaning the digitally designed prostheses matched the surgical defects as planned and could be positioned without improvisation. There were no major implant-related complications, and the authors report preservation of orbital and facial symmetry, the aesthetic goal that free-hand and delayed reconstruction approaches have historically struggled to guarantee consistently. The absence of implant-related problems in this cohort is particularly significant because cranial implants sit close to the brain, the eye and the paranasal sinuses, regions where malposition, infection or exposure can force revision surgery and undo the benefits of a single-stage strategy.

The authors conclude that single-stage resection with immediate CAD/CAM-assisted skull reconstruction for spheno-orbital meningiomas is feasible, safe and reproducible. The word reproducible matters as much as the others. Case reports of one-step tumor resection and cranio-orbital reconstruction with custom-made polymethylmethacrylate implants, and of image-guided meningioma resection with simultaneous computer-assisted cranio-orbital reconstruction, have appeared in the literature for nearly two decades, but scattered individual successes do not establish a standard of care. By codifying a standardized preoperative planning pathway and applying it uniformly across a series of patients, then auditing clinical, functional and radiological outcomes, the Muenster team has converted an ambitious concept into a protocol that other skull base centers can evaluate, adopt and refine. The authors suggest that combining tumor resection and patient-specific reconstruction within a single-stage procedure may offer practical advantages in the overall surgical pathway, sparing patients a second operation and its attendant risks, costs and delays.

Several caveats temper the enthusiasm. The study is retrospective, based on clinical data collected during routine patient care, and carries the limitations of that design, including the absence of randomization against alternative strategies and the possibility of selection effects in which patients were offered the combined procedure. The sample of 34 patients, while substantial for a rare tumor entity, is modest, and longer follow-up will be needed to confirm implant durability, tumor recurrence patterns and the stability of cosmetic and visual outcomes over years rather than months. The rates of transient diplopia and postoperative amaurosis also make clear that the single-stage approach does not by itself solve the fundamental surgical difficulty of spheno-orbital meningiomas; it reorganizes the treatment pathway around a technique that makes reconstruction more predictable. Even so, the study adds to a converging body of evidence, including systematic reviews of three-dimensional printing for customized bone reconstruction in these tumors and reports of augmented reality-assisted craniofacial reconstruction in skull base lesions, that digital planning and patient-specific implants are reshaping what is possible at the interface of neurosurgery, ophthalmology and reconstructive surgery. For patients facing a tumor that distorts both the skull and the face, the prospect of leaving the operating room with the disease removed and their anatomy restored in a single sitting is no longer a theoretical ambition but an increasingly documented clinical reality.

Subject of Research: Single-stage surgical resection and immediate CAD/CAM-assisted cranio-orbital reconstruction for spheno-orbital meningiomas

Article Title: Single-stage tumor resection and immediate CAD/CAM-assisted cranio-orbital reconstruction for spheno-orbital meningiomas: a standardized surgical workflow and outcome analysis

Article References: Fistouris, P., Ventura, E., Altayyar, A. A., Alanesi, A., Overstijns, M., Roelz, R., Brokinkel, B., & Schick, U. (2026). Single-stage tumor resection and immediate CAD/CAM-assisted cranio-orbital reconstruction for spheno-orbital meningiomas: a standardized surgical workflow and outcome analysis. Journal of Neuro-Oncology, 179(3), Article 91. https://doi.org/10.1007/s11060-026-05811-0

Image Credits: AI Generated

DOI: 10.1007/s11060-026-05811-0

Keywords: spheno-orbital meningioma, skull base surgery, CAD/CAM reconstruction, patient-specific implants, orbital decompression, exophthalmos, gross-total resection, visual acuity, 3D printing, neuro-oncology, cranioplasty, hyperostosis

The study, led by Ertugrul Senturk and Petek Erpolat of Gazi University Faculty of Medicine in Ankara, was designed to address a persistent evidence gap. Spinal ependymomas account for a substantial share of intramedullary spinal cord tumors in adults, yet no randomized trial has ever defined the optimal adjuvant strategy, and guidelines from the European Association of Neuro-Oncology acknowledge that recommendations for radiotherapy after subtotal resection rest on limited retrospective data. The TROD investigators restricted their analysis to adults aged 18 or older with histologically confirmed World Health Organization Grade 2 or Grade 3 tumors, excluding Grade 1 lesions such as myxopapillary ependymomas and any patient whose radiotherapy began more than six months after surgery, in order to create a analytically coherent cohort in which the timing question could be examined cleanly.

The methodological backbone of the study was conventional but rigorous. Clinical outcomes were estimated with Kaplan-Meier survival analysis, and prognostic factors were tested in multivariate Cox regression models, allowing the investigators to separate the independent contribution of each variable from the confounding influence of the others. Endpoints included local control, disease-free survival, progression-free survival, and overall survival, with local failure defined according to modern neuro-oncology response assessment criteria. With a median follow-up of 7.9 years in the Grade 2 cohort, the dataset offers something genuinely rare in this disease: a decade-scale view of what happens after adjuvant irradiation.

The dominant message from the Grade 2 cohort, which comprised 37 of the 45 patients, is that the extent of surgical resection remains the primary determinant of disease control. Gross total resection was achieved in 43.2 percent of these patients, and the results in that group were extraordinary: not a single local failure occurred, translating into 100 percent ten-year local control and disease-free survival. Among patients whose tumors were only subtotally resected, by contrast, 41.2 percent eventually experienced local failure, with five- and ten-year disease-free survival of 63.9 percent and 54.7 percent respectively, a difference that reached statistical significance at p = 0.006. In other words, even in an era when adjuvant radiotherapy is available, nothing the radiation oncologist delivers fully substitutes for a complete surgical excision when it can be achieved safely.

Yet the story is not simply one of surgery versus radiation. Despite the dramatic difference in local control, overall survival was statistically indistinguishable between the two resection groups, with ten-year overall survival of 88.9 percent after gross total resection versus 74.3 percent after subtotal resection, a difference that failed to reach significance at p = 0.70. This divergence between local control and survival underscores a clinical reality familiar to neuro-oncologists: spinal ependymomas often recur locally and slowly, and salvage treatment can extend life even when the initial disease control is imperfect. It also suggests that adjuvant radiotherapy, delivered to patients with residual disease, does meaningful work in suppressing local regrowth even if the ultimate survival benefit is harder to demonstrate in a cohort of this size.

The most consequential finding, however, concerns timing. Among non-GTR patients who had no evidence of tumor dissemination at the start, a surgery-to-radiotherapy interval exceeding 1.5 months emerged as the sole independent predictor of early recurrence, with the enormous hazard ratios noted above reaching significance at p = 0.04 for both disease-free and progression-free survival. The authors conclude that early adjuvant radiotherapy, ideally initiated within about six weeks of surgery, should be regarded as a critical management strategy for patients with residual Grade 2 disease. Because this was a retrospective analysis, the result cannot prove causation in the way a randomized trial could, and patients referred late for radiotherapy may differ in ways the models cannot fully capture. Even so, a signal this strong, in the largest direction imaginable, gives treating physicians a concrete, actionable benchmark in a field that has operated largely on intuition.

The study also clarified which patients face the steepest odds regardless of treatment. Younger age at diagnosis and the presence of baseline spinal dissemination were both independent adverse prognostic factors for progression and mortality. For patients who presented with spinal dissemination at the outset, the progression rate reached 60 percent and median overall survival collapsed to just 15.2 months, a sobering figure that illustrates how quickly this disease can shift from an indolent, surgically manageable problem to a disseminated, life-threatening one. These findings argue for careful baseline neuraxis imaging and heightened surveillance in any patient whose tumor has already seeded the cerebrospinal fluid pathways.

Grade 3, or anaplastic, ependymomas behaved very differently. In this small subgroup, five-year local control, progression-free survival, and overall survival were 56.3 percent, 41.7 percent, and 75.0 percent respectively, and 62.5 percent of patients progressed. Interestingly, gross total resection did achieve complete local control even in these aggressive tumors, but distant metastasis remained the dominant pattern of failure, occurring in 60 percent of progressive cases. This dissociation between local and distant control carries an important implication: for anaplastic tumors, excellent local therapy is not enough, and the field may need to think in terms of systemic or craniospinal strategies to address the risk of dissemination, an area where current evidence remains thin and clinical trials are urgently needed.

The technical details of the radiation itself matter as well, even though the published abstract centers on timing and extent of resection. Modern practices, including image-guided and increasingly stereotactic approaches to the spine, allow high conformal doses to be delivered to residual tumor while sparing the exquisitely radiation-sensitive spinal cord, and the study’s data collection aligned with standard toxicity grading frameworks to capture treatment-related harm. The authors report no funding sources and no competing interests, and the dataset is available from the corresponding author upon reasonable request, inviting external validation of their findings.

What should patients and clinicians take away from this work? First, gross total resection remains the gold standard, and every effort should be made to achieve it when it can be done without unacceptable neurological risk, an aim increasingly supported by intraoperative neuromonitoring. Second, when residual disease is left behind, adjuvant radiotherapy demonstrably provides effective local control in Grade 2 tumors, and delaying it beyond roughly six weeks appears to carry a substantial and measurable cost in recurrence risk. Third, Grade 3 histology and initial spinal dissemination mark patients for intensified surveillance and, plausibly, for future trials of more aggressive combined-modality therapy. In a rare disease where no single institution will ever accumulate enough patients to answer these questions alone, the multicenter TROD model itself deserves credit: by pooling nearly three decades of experience across ten centers, the group has produced one of the clearest evidence-based guides yet for a treatment dilemma that neurosurgeons and radiation oncologists confront every week.

Subject of Research: Long-term outcomes of adjuvant radiotherapy in adult WHO Grade 2 and 3 spinal ependymomas

Article Title: Long-term outcomes after adjuvant radiotherapy in adult spinal ependymomas: a multicenter study by the trod Neuro-Oncology research group (07 − 005)

Article References: Senturk, E., Erpolat, P., Kamer, S., Yücel, B., Barış, B. Ş., Bayatfard, P., Atasoy, B., Çetinayak, H. O., Atasever Akkaş, E., Baltalarlı, P. B., & Delikgöz Soykut, E. (2026). Long-term outcomes after adjuvant radiotherapy in adult spinal ependymomas: a multicenter study by the trod Neuro-Oncology research group (07 − 005). Journal of Neuro-Oncology, 179(2), Article 77. https://doi.org/10.1007/s11060-026-05793-z

Image Credits: AI Generated

DOI: 10.1007/s11060-026-05793-z

Keywords: spinal ependymoma, adjuvant radiotherapy, gross total resection, subtotal resection, local control, disease-free survival, progression-free survival, overall survival, anaplastic ependymoma, spinal dissemination, recurrence timing, neuro-oncology